US FDA approves Xeljanz (tofacitinib) tablets and oral solution for the treatment of active polyarticular course juvenile idiopathic arthritis

Approval was based on RCT (n=225) which showed occurrence of disease flare in patients treated with tofacitinib was statistically significantly lower compared to patients treated with placebo (31% vs. 55%, respectively, p=0.0007) at week 44.

Source:

Biospace Inc.